Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements align with labeled information (e.g., indications, pregnancy/embryo-fetal toxicity, key contraindications such as pregnancy and PDE-5/nitrates), but many claims are not supported or cannot be verified from the provided FDA label excerpts (e.g., generic substitution/regulatory timing, strength/bioavailability equivalence, specific safety characterization, interaction details beyond nitrates/nitric oxide donors and PDE-5 timing, and switching/monitoring specifics).
Category Scores
Accurate Statements
Riociguat is used for pulmonary arterial hypertension (WHO Group 1).
Supported (Indications section provided): Adempas indicated for adults with pulmonary arterial hypertension (PAH).
Riociguat is used for chronic thromboembolic pulmonary hypertension (CTEPH).
Supported (Indications section provided): Adempas indicated for adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
A key safety risk of riociguat is low blood pressure symptoms such as dizziness and fainting.
Partially supported/uncertain: the provided label excerpts relate to pregnancy/REMS, contraindications, and do not include this specific phrasing; cannot confirm from supplied excerpts.
Riociguat has drug interactions, especially with drugs that affect blood pressure and some nitrates.
Partially supported: contraindication with nitrates/nitric oxide donors is present in provided excerpts (4.2). Additional interaction details beyond provided excerpts cannot be verified.
Monitoring requirements during titration and after switching are relevant for riociguat.
Not verifiable from provided excerpts: monitoring language for titration/switching is not included in the supplied label sections.
A switch to a generic riociguat should be coordinated with the prescriber and not done mid-titration without guidance.
Not verifiable from provided excerpts: no generic switching/titration coordination guidance is present in the supplied label sections.
Unsupported Statements
A marketed generic of Adempas would mean a version of riociguat approved for the same use and able to replace the brand under pharmacy substitution rules.
No content in the provided FDA label excerpts addresses generic approval scope or pharmacy substitution rules.
Generic riociguat availability depends on the country and on current regulatory approvals.
Not addressed in provided label excerpts (label does not discuss country-by-country generic availability).
Generic (or authorized) riociguat availability may vary by country.
Not addressed in provided label excerpts.
Adempas comes in multiple dose strengths.
Dose-strength listing is not included in the provided excerpts.
Even when generics exist, some plans may require brand or prior authorization for substitution.
Not addressed in provided FDA label excerpts (payer/formulary rules are not in label).
Generic riociguat entry is typically delayed by patent and regulatory exclusivity protections covering the reference product.
Not addressed in provided label excerpts.
The timing of when a generic can enter depends on patent expiry dates (and any extensions).
Not addressed in provided label excerpts.
The timing of when a generic can enter depends on regulatory exclusivity terms that vary by jurisdiction.
Not addressed in provided label excerpts.
Ongoing litigation or certification pathways can delay approval and/or launch of a generic.
Not addressed in provided label excerpts.
When a generic is approved, it should match Adempas in key ways such as having the active ingredient riociguat.
Label excerpts do not discuss generic equivalence requirements.
When a generic is approved, it should match Adempas in strength and dosing equivalence.
Label excerpts do not discuss generic equivalence requirements.
When a generic is approved, it should match Adempas in bioavailability/absorption performance as required by regulators.
Label excerpts do not discuss generic equivalence requirements.
Riociguat dosing is individualized and linked to tolerability and blood pressure.
The provided excerpts do not include dosing/titration guidance.
A key safety risk of riociguat is low blood pressure symptoms such as dizziness and fainting.
Provided excerpts do not include this specific adverse effect description for low blood pressure.
Monitoring requirements during titration and after switching are relevant for riociguat.
Provided excerpts do not include monitoring recommendations for titration or after switching.
A switch to a generic riociguat should be coordinated with the prescriber and not done mid-titration without guidance.
Provided excerpts do not include generic switching guidance.
Contradictions
Important Omissions
Pregnancy/embryo-fetal toxicity prevention details (pregnancy testing schedule and contraception requirements, including duration after stopping) are not included in the listed AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims about generic switching, titration, and monitoring are not supported by the provided label excerpts; missing pregnancy prevention details are material to safe use but not claimed in the provided statements list.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many statements (especially regarding generic substitution, regulatory timing, equivalence, and switching/titration monitoring) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to information present in the provided Adempas prescribing information excerpts (e.g., labeled indications; contraindications such as pregnancy and nitrates/nitric oxide donors; embryo-fetal toxicity warning with required pregnancy testing and contraception/REMS requirements). Avoid adding statements about generic approval/substitution timing and switching practices unless explicitly supported by the label excerpts.